17,261 trials
Alzheimer's Disease
Primary: Total Score of Alzheimer's Disease Assessment Scale - Cognition Subscale (ADAS-COG)From Best Total Score (0) to Worst Total Score (70) — -1.3; -2.9; -1.5 units on a scale
Metastatic Breast Cancer
Primary: Percentage of Participants Showing an Overall Response As Assessed by the Independent Radiology Reader and by the Investigator — 37; 45; 49; 35 percentage of…
Age-Related Macular Degeneration
Primary: Rate of Change in Area of Geographic Atrophy (GA) in the Study Eye at 24 Months as Compared to Baseline — 0.102 MPS DA/month
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Prostate Cancer
Primary: Number of Patients With Stable Disease at 4 Months. — 2; 5 participants
Papulopustular Rosacea
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward) — 43.4…
Multiple Sclerosis
Primary: Double Blind Period: Percentage of Participants With Grade 3 or 4 (Common Terminology Criteria for Adverse Events [CTCAE] v 4.0) Hematological or Liver Toxicity — 63.71…
Atrophy · Vaginal Diseases
Primary: Mean Change From Baseline in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear — -3.0; -2.8; -24.1; -26.8 percentage of parabasal cells
Chromophobe Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma · Papillary Renal Cell Carcinoma
Primary: Maximum Tolerated Dose (MTD) of BAY 43-9006 (Sorafenib)in Combination With Bevacizumab (Phase I) — 200 mg
Adenocarcinoma of the Lung · Adenosquamous Cell Lung Cancer · Bronchoalveolar Cell Lung Cancer
Primary: Time to Progression — 4.63 months
Pathological Processes in the Posterior Fossa · Dura Defects
Primary: Incidence of Cerebrospinal Fluid (CSF) Leakage Observed After Surgery — 74.07; 78.13 percentage of participants — p=0.7159
Adrenal Cortex Neoplasms
Primary: Response Rate (RR) of Axitinib Administered Daily, in Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer (ACC) — 0; 0; 13; 0 Participants
Breast Cancer
Primary: Response Rate (Complete and Partial, Confirmed and Unconfirmed) — 29 participants
Human Immunodeficiency Virus 1
Primary: Change From Baseline to Week 24 in Brachial Artery Flow Mediated Vasodilatation (FMD): Median Change in FMD (%) — -4.8; -0.6 Percentage of brachial artery diameter…
Breast Cancer
Primary: Progression-free Survival (PFS) — 6.6; 3.8 Months — p=0.12